Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers March 23, 2019
Pharmacy Choice - Pharmaceutical News - Easton Announces Status Updates on its $2,600,000 Framing Contract to Construct 150 Homes, Including New Additional Project - March 23, 2019

Pharmacy News Article

 1/11/19 - Easton Announces Status Updates on its $2,600,000 Framing Contract to Construct 150 Homes, Including New Additional Project

TORONTO, ON, Jan. 11, 2019 (GLOBE NEWSWIRE) via NEWMEDIAWIRE Easton Pharmaceuticals Inc. (OTC:EAPH) provides operational update on its $2,600,000 CDN framing contract to build approximately 150 homes just outside of Toronto, Ontario including possible new project.

Easton recently announced that it has entered into a $2,600,000 CDN framing contract and has commenced work on the framing of approximately 150 homes with a well-known prominent regional builder.

Easton can disclose that it has collected approximately $150,000 CDN in payments over the past 30 day period since operations commenced. Easton's Director, Vince Demasi, who is also the operational manager for the project, stated that the good weather conditions up to now and the well-organized crew, have resulted in no delays with our building operations. Since the framing is ahead of schedule and all 30 full time employees being very productive and allowing East, has been presented with another possible building contract to construct up to 200 residential units in Welland, Ontario, Canada.

Additional details are expected to be made available in the next few weeks on a possible lucrative $30,000,000 building project in addition to its recently announced Cobourg, Ontario development project to build 42 residential units over the next 3 years, with the first phase approved and ready for 6 units in an existing mansion.

Easton is currently in the process of completing and filing its September 31, 2018 quarterly financial Statements and its December 31, 2018 year-end financial Statements following which, it will initiate an audit through auditors the Company has selected.

About Easton Pharmaceuticals

Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries. The Company previously developed and owned an FDA-approved wound-healing medical drug and currently owns topically delivered drugs to treat cancer and other therapeutic products to treat various conditions that are all in various stages of development and approval. Easton, together with BMV Medica S.A. own the exclusive distribution rights in Mexico and Latin America for two patented women's diagnostic products and a novel natural treatment for Bacterial Vaginosis, which they have sub-licensed to Bayer and Gedeon Richter. In addition, a generic cancer drugs line is being developed for sale in Mexico. The company's gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of other drugs. As part of its strategic growth plan, the Company will be entering new lucrative market segments globally, including Gaming, Real Estate and Hospitality, among others.

For More Information on Easton and Affiliated and Partner Company's Visit:

http://www.eastonpharmaceuticalsinc.com

http://finance.yahoo.com/q?s=eaph

https://twitter.com/eastonpharma

Safe Harbor

This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when certain words or phrases such as "hope", "positive", "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.

CONTACT INFORMATION:
Evan Karras / CEO / President
Tel: 647.362.5700 
Email: eastonpharma@protonmail.com

Easton Logo.png

Source: Easton Pharmaceuticals Inc.


2019 GlobeNewswire, Inc.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Mar 24: A Look Inside the Top 200 Drugs
Mar 25: Medication Use During Pregnancy & Lactation
Mar 26: Nutrigenomics - Nutritional Influences on the Genome
Mar 27: ADHD in Children & Adults: Etiology, Pathology, Pharmacotherapy
Mar 28: Alternatives and Complements to Prescription Pain Management
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415